These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Current pharmacotherapy of Parkinson's disease]. Takáts A Orv Hetil; 2000 Mar; 141(10):483-8. PubMed ID: 10750400 [TBL] [Abstract][Full Text] [Related]
8. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design. Rascol O Neurology; 2009 Feb; 72(7 Suppl):S51-8. PubMed ID: 19221315 [TBL] [Abstract][Full Text] [Related]
9. Quantification of disease progression and dropout for Alzheimer's disease. William-Faltaos D; Chen Y; Wang Y; Gobburu J; Zhu H Int J Clin Pharmacol Ther; 2013 Feb; 51(2):120-31. PubMed ID: 23211395 [TBL] [Abstract][Full Text] [Related]
10. Realistic expectations for treatment success in Alzheimer's disease. Geldmacher DS; Frolich L; Doody RS; Erkinjuntti T; Vellas B; Jones RW; Banerjee S; Lin P; Sano M J Nutr Health Aging; 2006; 10(5):417-29. PubMed ID: 17066215 [TBL] [Abstract][Full Text] [Related]
11. Design of clinical trials of gene therapy in Parkinson disease. Lewis TB; Standaert DG Exp Neurol; 2008 Jan; 209(1):41-7. PubMed ID: 17920590 [TBL] [Abstract][Full Text] [Related]
12. [Clinical pharmacology and therapeutic aspects in certain degenerative neurological diseases]. Maloteaux JM Bull Mem Acad R Med Belg; 1996; 151(10-11):429-32; discussion 432-4. PubMed ID: 9491620 [TBL] [Abstract][Full Text] [Related]
13. Disease system analysis: basic disease progression models in degenerative disease. Post TM; Freijer JI; DeJongh J; Danhof M Pharm Res; 2005 Jul; 22(7):1038-49. PubMed ID: 16028004 [TBL] [Abstract][Full Text] [Related]
14. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Fleming SM; Delville Y; Schallert T Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106 [TBL] [Abstract][Full Text] [Related]
15. The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic. Horstink MW; van Engelen BG Arch Neurol; 2003 Aug; 60(8):1170-2; author reply 1172-3. PubMed ID: 12925381 [No Abstract] [Full Text] [Related]
16. Do cholinesterase inhibitors slow progression of Alzheimer's disease? Farlow MR Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366 [TBL] [Abstract][Full Text] [Related]
17. [Natural progression of Alzheimer's disease (AD): a perspective on possible therapies for advanced AD]. Yanagisawa K Rinsho Shinkeigaku; 2004 Nov; 44(11):921-3. PubMed ID: 15651332 [TBL] [Abstract][Full Text] [Related]
18. Drug Insight: new drugs in development for Parkinson's disease. Colosimo C; Fabbrini G; Berardelli A Nat Clin Pract Neurol; 2006 Nov; 2(11):600-10. PubMed ID: 17057747 [TBL] [Abstract][Full Text] [Related]
20. N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for? Martínez-Banaclocha MA Med Hypotheses; 2012 Jul; 79(1):8-12. PubMed ID: 22546753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]